One goal: discovering new treatments
Digestive diseases are among the most enigmatic and complex scientific areas of today's medicine. They are at the crossroads of multiple research fields: genetics, immunology, infectiology, nutrition, etc.
These diseases require multidisciplinary approaches involving scientists, doctors and food manufacturers, difficult to coordinate in the current model of research organization. This was one of the main motives for creating the DigestScience foundation.
Founded by scientists and clinicians, DigestScience aims at guiding, uniting and encouraging new lines of research, developing new treatments and urgently improving the patients' quality of life.
DigestScience's research strategy is based on ambitious programs that provide selected teams with appropriate means to carry out their investigations. The funding offered by DigestScience is among the most important at the European level, as far as these diseases are concerned.
Initiating ambitious scientific projects, DigestScience organizes international congresses, gathering top international experts of digestive diseases, to develop new leads in research and treatment.See upcoming workshops
Microbiome and intestinal fibrosis
1st grant awarded jointly by ECCO* and DigestScience
* European Crohn and Colitis Organization
Evolution towards fibrosis is a serious complication of IBDs as it obstructs the digestive duct, often leading to repeated surgeries that affect the patient's quality of life. If intestinal bacteria live in harmony in healthy subjects, they may activate an immune response in the context of IBDs, eventually resulting in the development of fibrosis. The objective of this work is to identify how bacteria affect the formation of this scar tissue, and open the door for developing new therapeutic options.
Bacteriophages and Intestinal Flora
Major therapeutic prospects. his innovative research program is conducted by 3 internationally recognized French teams. Led by Laurent Debarbieux from the Institut Pasteur in Paris, this work demonstrates the key role of bacteriophages in the balance of intestinal flora, and their potential therapeutic, diagnostic and prophylactic uses.
A budget worth 400,000€, a brand new ecological approach of digestive diseases.
Cell Therapy in Crohn's Disease
Towards a brand new approach of Crohn's disease treatment based on stem cells. The hepato-gastroenterology department of Leiden University (Netherlands) was selected in 2009 among 25 candidate European laboratories for its project "Mesenchymal Stromal Cell Therapy for Crohn's Disease". DigestScience has invested a record budget of 1 million euros over 2 years to highlight the proof of concept of this innovative therapeutic strategy.
A parasitic enzyme as a new therapeutic tool for IBDs
The increasing occurrence of immune system disorders, including allergies, autoimmune diseases or IBDs, seems to be related to recent changes in the environment. The absence of parasitic infections in industrialized countries or the intensive anti-parasite treatments in emerging countries have probably disrupted the regulatory mechanisms that had been in place for a long time in the evolution, and may explain, at least partially, the dramatic increase of inflammatory diseases. This hypothesis is supported by numerous experimental evidences showing the protective effects of infection by various helminth parasites in models of immune system conditions.
The harmful effect of cellular microparticles sourced from Crohn's disease patients. This program is coordinated by Professor Jean-Marie Reimund, Caen CHU.
World's largest registry on Crohn's disease and Ulcerative Colitis. Covering almost 6 million individuals, i.e. 9.3% of the French population, this international general population-based epidemiology program has been recognized for 26 years for its numerous works.
Aluminium and intestinal inflammation
Aluminium, a new risk factor for Crohn's disease and Ulcerative Colitis? An innovative work on aluminium, the presence of which in industrialized countries has skyrocketed by over 350%, and its undoubted role in intestinal inflammation in animal models...
Bacteria transmission in Crohn's Disease
Towards a preventive treatment of Crohn's disease? This collaborative work of Inserm laboratory U995 "Inflammatory digestive diseases: pathophysiology and development of therapeutic targets", Lille, and Mount Sinai Hospital in New York will be the most thorough research studying microbiota in Crohn's disease patients.